Neurodegenerative Disease Test Kit

LncRNAs are the most tissue-specific family of RNAs, which is a new horizon for diagnostic and therapeutic applications in the field of NDs. The identification of NeuroLINCs’ lncRNAs was conducted through deep sequencing of human blood from patients with varying stages of Alzheimer’s disease, patients with other types of dementia, cognitively intact healthy controls, and postmortem brains.input:
output:Expression levels were compared to select brain-enriched lncRNAs that are differentially expressed in the blood.

A total of 7494 lncRNAs, including 1816 novel lncRNAs that have never been previously described, were identified. The NeuroLINCs panel includes those that correlate with the relevant biomarkers of Alzheimer brain pathology (CSF Abeta or Tau) and neurodegeneration (volumetric scores of mediotemporal and hippocampal atrophy).Features and advantagesFIRST IN-CLASS TESTfor the measurement of brain-enriched IncRNAs in peripheral blood.

FIRST TEST OF BLOOD LNCRNA BIOMARKERS

for the diagnostic of MCI, early Alzheimer, and other dementia types.input:
output:An examination of a novel classof therapeutic targets.PROPRIETARY LISTinput:
output:of IncRNAs that have been enriched in the brain.input:
output:Streamlined processinput:
output:
Samples were collected non-invasively to investigate lncRNAs.PAXgene, plasma, brain tissue, and PBMCs have already been validated.input:
output:The results are highly reproducible, indicating exceptional analytical performance.input:
output:A total of 7494 lncRNAs were detected, with 5930 lncRNAs in PAXgene and 3166 in Plasma, demonstrating a high level of sensitivity.input:
output:ENHANCE YOUR BIOMARKER PROJECTS AND DEVELOPMENT PROGRAMSinput:
output:We offer unwavering support in a variety of fields, from the initial concept to regulatory qualification, with extensive experience in each stage.